<DOC>
	<DOCNO>NCT00831415</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety desvenlafaxine succinate sustain release tablet 10-month open-label treatment Japanese subject major depressive disorder ( MDD ) . The secondary objective evaluate long-term response subject receive desvenlafaxine succinate sustain release tablet clinical global evaluation , general well-being absence symptom .</brief_summary>
	<brief_title>Study Evaluating Long-Term Safety Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients complete doubleblind therapy shortterm study indication major depressive disorder ( MDD ) , include schedule evaluation , major protocol violation study event , opinion investigator , would preclude subject 's entry longterm , openlabel study . Clinically important abnormality baseline ( day 56 shortterm study ) physical examination , unresolved clinically significant abnormality electrocardiogram ( ECG ) , laboratory test result , vital sign record day 56 previous shortterm study indication MDD .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Open-label Long-term extension study</keyword>
</DOC>